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In recent years new anti-emetic agents have been developed.These drugs greatly reduce or
eliminate chemotherapy -related nausea and vomiting.
Introduction of new drugs as G-CSF ( Neupogen), rHuGM-CSF ( Leucomax ) and Eprex
(rHu-EPO) gave the possibility to prevent serious chemotherapy side-effects like leucopenia and
anaemia.
Supportive treatment in cancer patients enormous influence the quality of life and reduce
therapy- related anxiety.
In our Oncological Clinic this supportive treatment has been used for 3 years allowing more
aggresive therapy.
P·REFACE
In 1984 Till, McNeil and Bush defined quality
of life as a total idea including psychical and
social activity, physical action and profitable
aspects of being in a good frame of mind as well
as negative ones coused by disease and
invalidity [Dawid M.D., 1993].
The quality of life is estimated subjectively
and only the patient can compare his present
condition with the one he would like to have and
which would be a normal one for him [Dawid
M.D., 1993]. So he patient's opinion is the most
important and should be taken into account
every time when it is possible.
When the patient cannot answer the question
about his quality of life then the opinions of people
who look after him could be considered but still
one should be careful because considerable
disagreements in evaluations of quality of life
among opinion of doctors, relatives and patients
have been noticed.
The quality of life depends on patient's
physical and psychical condition, so all methods
of adjuvant therapy are very valuable and should
be videly used in oncological clinic.
Recently a new group of antiemetic drugs, 5-
HT 3- receptor antagonists [Aapro, 1993;
Ramlau et ai, 1993; Kytril, 1993] have been
applied in clinic. Those agents help eliminate
nausea and vomiting to a great extent.
Chemotherapy induced nausea and vomiting
were the reason for refusing futher therapy by
some patients although it could be curative. As a
consequence of aggravation of cancer
patient'shealth, the quality of life worsened.
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At the same time a new possibility of preventing
serious chemotherapy related side-effects like
granUlocytopenia and anaemia appeared. This
was connected with administration of
haematopoietic growth factors such as
Neupogen (G-CSF), Leucomax (rHuGM-CSF)
and Eprex (rHu-EPO) [Neupogen, Leucomax,
1993; Eprex].
Application of a new supportive methods in
patients receiving cytotoxic drugs has caused a
noticeable improvement of therapy conditions
and treatment-related anXiety. Consequently
the quality of life of our patients has improved.
NAUSEA AND VOMITING
Development of chemotherapy and new
chemotherapy regimens application reduces
tumour mass and improves response rates,
therefore it leads to extention of patients'
survival time and improvement of quality of their
lives. However, cytotoxic agents are also toxic
and induce very unpleasant side-effects like
nausea and vomiting .Those drawbacks make
therapy unbearable. Moreover, nausea and
vomiting were the main reason for refusing
chemotherapy by some patients although it
could be curative. Unpleasant and harmful side-
effects must be prevented or reduced in order to
make the treatment acceptable by the patients
and the medical staff.
Additionally, nausea and vomiting can bring
weakness and exhaustion which interfere with
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everyday patient's activity. Another conseque-
nce of side-effects mentioned above is lasting
anorexia leading to chronic malnutrition and loss
of liquids which needs intravenous supplement.
It is considered that there are two
anatomically and functionally different areas
which are responsible for regulation of vomiting
reflex .They are located in medulla oblongata
[Ramlau et ai, 1993].
First of them, Chemoreceptor trigger
zone, is situated on both sides of the bottom of
fourth cerebral ventricle. Chemoreceptor trigger
zone is in contact with blood and cerebrospinal
fluid abounding with neurotransmitters. This area
adheres to the second one-Vomiting centre. It is
essential for vomiting reflex. Vomiting centre is
located close to Respiratory centre and Saliva
secretion regulating centre. Those centres coor-
dinate secretion .of mucous glands with involu-
ntary contractions of diaphragm, thoracic and abdo-
minal muscles, which are due to vomiting effect.
At first cytotoxic drugs affect
Chemoreceptor trigger zone. Then impulses
reach Vomiting centre. The impulses can also go
by way of the throat and the upper part of
gastrointestinal tract through afferent fibres of
vagus nerve and symphatetic system.Certain
parts of cerebral cortex may stimulate Vomiting
centre, too.
NEW ANTI-EMETIC DRUGS
Zofran (ondansetron )-5-HT 3 receptor
antagonist [3] is very effective in controlling
chemotherapy and radiotherapy- related nausea
and vomiting, much more effective than
metoclopramide. From April till May 1991 in
Chemotherapy Ward, Oncological Clinic of
K.Marcinkowski University School of Medicine in
Poznan 10 patients treated with chemotherapy (
5 with cisplatin and 5 with other drugs ) were
administered Zofran ( from G/axo ).Cisplatin-
treated patients were given 8 mg of Zofran
intravenously before cisplatin, the second and
the third ampoule ( a 8 mg ) every 8 hours. Next
day and the following ones Zofran was given in
tablets in case of emesis continued.
The other 5 patients were administered 8
mg of Zofran intravenously before cytotoxic
drugs and next 8 mg in tablets every 8
hours.The results were estimated in a 5- grade
evaluation scale in comparison with previously
aplied anti-emetic drugs ( the grades were: very
good, good, average, poor, no effective). Very
good results were obtained by 80 % of patients
and good ones by 20 %. In three cases intensive
vomiting- resistant to previous antiemetic drugs-
stopped. Up till now many patients have been
given Zofran many times. The overall results are
similar to the mentioned above.
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Navoban ( tropisetron ) is another
antagonist of serotonin-receptor [1].lt has been
used in Oncological Clinic in Poznan for 3 years.
It is a product of Sandoz.
Doing research together with Radiotherapy
Clinic of Oncology Institute in Gliwice we had a
chance to prove a high anti-emetic efficacy of
Navoban. In randomised controlled clinical trial
quality of Navoban was compared with efficacy
of traditional anti-emetic agents i.e.
dexamethasone and metoclopramide.
Good results (minimal nausea and no more
than 2 episodes of vomiting) were obtained in
89 % of patients receiving Navoban and in 38 %
of patients receiving dexamethasone and
metoclopramide. In cisplatin-treated patients
good results were obtained in 86 % of them,
while for other cytotoxic drugs in 95 %.
Very good results (no nausea and
vomiting ) were noted in 69 % of Navoban-and
only in 17 % of dexamethasone and
metoclopramide-administered patients.
Kytril (granisetron ) [5] is the third of anti-
emetic drugs (serotonin-receptor antagonist ).
According to the producer Smith Kline Beecham
Kytril is the best anti-emetic agent of 5-HT 3-
receptor antagonists.
In August and September 1994 antiemetic
efficacy of Kytril was evaluated in our Clinic. 31
patients were administered 3 mg of Kytril
intraveniously directly before cytotoxic drugs as
cisplatin, cyclophosphamide, epirubicin,
dacarbazine. On the first· day of treatment
nausea and vomiting appeared in 30 % of the
patients. Than, on the following days in only 10
% of them.
Now anti-emetic quality of granisetron
combined with corticosteroids is under
randomised controlled study in our Clinic.
GROWTH FACTORS AND IMPORTANCE OF
THEIR INTRODUCTION INTO ONCOLOGY
CLINIC
Application of Neupogen ( filgrastim,
G-CSF ) [Neupogen], a product of Roche, as a
haematopoetic growth factor was initiated in the
years 1991-1993.
It is the first of various growth factors,
which influences number of white cells
(neutrophils). Thus Neupogen is applied in
prophylaxis of infections caused by bone
marrow supression as a consequence of
chemotherapy.
The authors ( J.A.Green ) using
Neupogen on a large scale tend to administrate
cytotoxic drugs in maximum dose and in a wright
time.One should also consider the economic
side of employing growth factors in reducing
costs of treatment and first of all in improving the
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quality of patient life. Application of high doses of
cytotoxic drugs with Neupogen may give some
good results in treatment of common doses-
resistant tumours. Intravenous or subcutaneous
G-CSF injections ( 0,5 MU I kg I 24 hrs ) on the
following day after chemotherapy are
recommended.
According to W. Hiddeman and co-
workers employing filgrastim in acute myeloid
leucaemia reduced mortality from 39 % to 14 %.
Neupogen has been succesfully administered
several times in our Clinic. Leucomax (rHu GM-
CSF -molgramostim) [Leucomax, 1993], a
product of Sandoz and Schering-Plough has
been shown as another useful haematopoietic
growth factor in our Clinic. It is a water soluble,
127 amino acids-containing recombinant human
granulocyte -macrophage colony stimulating
factor. Molgramostin is produced by a strain of
Escherichia coli bearing a genetically engineered
plasmid which contains a human GM-CSF
gene.Leucomax is indicated:
- in patients receiving myelosuppressive therapy
( cancer chemotherapy) to reduce the severity
of neutropenia, thereby reducing the risk of
inJection and allowing better adherence to the
chemotherapeutic regimen;
- in patients presenting with other bone marrow
failure states ( myelodysplastic syndromes I
aplastic anaemia) to reduce the risk of infection
originating from leucopenia;
- in patients undergoing autologous or syngeneic
bone marrow transplantation to accelerate
myeloid recovery; - in patients with leucopenia
associated with infections ( inc!. HIV)
- in patients with AIDS-related cytomegalovirus (
CMV ) retinitis.
Leucomax dosing regimens vary according to
the indication for therapy (in cancer
1993 :1-26
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. chemotherapy 5 t010 micrograms I kg per day of
molgramostim administered subcutaneously
Treatment should be initiated 24 hours after the
last dose of chemotherapy and continued for 7
to 10 days.
Eprex ( r-Hu EPO-erythropoietin ) made
by Janssen-Cilag can improve the quality of life
of our patients by increasing of haemoglobin
level and thus relieves anaemia- connected
symptoms (like weakness ).Well tollerated Eprex
may reduce the need for transfusion, therefore
eliminate risks associated with blood transfusion.
Eprex has been administered cancer patients (
in ovary- cancer especially ) since december
1993. Subcutaneous injections of Eprex in dose
of 150 to 300 IU I kg, 3 times a week, are
recommended.
The only disadvantage of those new
drugs, especially the growth factors, may be
their very high price.
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